LncRNA KCNQ1OT1在急性髓系白血病患者中的表达及其临床意义

Expression and Clinical Significanceof LncRNA KCNQ1OT1 in Patients with Acute Myeloid Leukemia

目的:探讨LncRNA KCNQ1OT1在急性髓系白血病(AML)患者中的表达,分析其与临床预后的相关性。方法:收集68例AML患者,其中48例急性髓系白血病(acute myeloid leukemia,AML)患者和20例达到完全缓解(complete response,CR)的AML患者及30例性别年龄相匹配的缺铁性贫血患者(作为对照组)的外周血液标本,采用实时荧光定量PCR(qRT-PCR)检测LncRNA KCNQ1OT1的表达,分析其表达与患者临床病理特征及预后的关系。结果:LncRNA KCNQ1OT1在AML患者中的表达较完全缓解者及缺铁性贫血患者均明显增高(F=14.67,P<0.001),而LncRNA KCNQ1OT1在20例AML-CR组患者与30例对照组患者中的表达差异无统计学意义(P>0.05)。LncRNA KCNQ1OT1的表达与患者的NCCN风险分级及生存状态相关;高表达LncRNA KCNQ1OT1患者的中位总生存时间较低表达者明显缩短(P<0.05)。结论:LncRNA KCNQ1OT1参与调节AML的发生和发展,可作为AML患者潜在的预后标志物和治疗靶点。

Objective： To investigate the expression of LncRNA KCNQ1OT1 in patients with acute myeloid leukemia（AML） and to analyze the relation of LncRNA KCNQ1OT1 expression levels with clinicopathological features.Methods：A total of 68 patients with AML were enrolled in the study,48 out of them were suffered from acute myeloid leukemia（AML） and 20 reached to complete remission（CR）,30 age-matched patients with iron-deficient anemia were included in control group,the peripheral blood samples of all the patients were collected,and the real-time fluorescent quantitative PCR（qRT-PCR） was used to detect the expression of LncRNA KCNQ1OT1,meanwhile,the correlation of its expression with clinicopathological characteristics and prognosis was analyzed.Results： The expression of LncRNA KCNQ1OT1 in AML patients was significantly higher than that in the patient with complete remission and iron-deficient anemia（ F = 14.67,P〈0.01）.The expression of LncRNA KCNQ1OT1 was not significantly different between 20 cases of AML-CR and 30 cases of iron-deficient anemia（ P〉0.05）.The expression of LncRNA KCNQ1OT1 was associated with NCCN risk grade and survival status in patients with AML.The median overall survival time was significantly shorter in patients with high expression of LncRNA KCNQ1OT1 than that in patients with low expression（ P〈0.05）.Conclusion： LncRNA KCNQ1OT1 may be involved in the regulation of AML.Expression of LncRNA KCNQ1OT1 and NCCN risk score can be used as biomarkers of prognosis in the patients with AML and may be a potential prognostic marker and therapeutic target for AML patients.